As per the agreement, Actelion will receive exclusive rights to commercialize XIAFLEX (collagenase clostridium histolyticum) in Canada, Australia, Brazil and Mexico upon receipt of the respective regulatory approvals.
Actelion will pay Auxilium $10m upfront and will also make up to $16m in potential regulatory, pricing and reimbursement milestone payments and $42.5m in potential sales milestone payments.
Auxilium will also receive increasing tiered double-digit royalties based on sales of XIAFLEX in Actelion’ territories and will supply product to Actelion at a predetermined cost.
Auxilium is responsible for the global development of XIAFLEX in Peyronie’s disease and for all clinical and commercial drug manufacturing and supply.
Actelion will be responsible for clinical development activities and associated costs corresponding to any additional trials required for specific territories.
Auxilium CEO and president Adrian Adams said the companies have forged a partnership, which they believe has the opportunity to offer, subject to regulatory approval, the first, effective nonsurgical treatment for two diseases in multiple new geographies.